Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COVSurf trial of nebulized surfactant for severe viral pneumonia
ISRCTN12839523Phase 2Recruiting
- Sponsor
- University Hospital Southampton NHS Foundation Trust
- Start
- Jul 2024
- Modality
- Recombinant Proteins and Enzymes
01
Overview
Phase 2, randomised, open-label trial in viral pneumonia and coronavirus disease 2019 (COVID-19) comparing Nebulized Alveofact plus standard of care with Standard of care control (2 arms). Primary endpoints: Change in PaO2/FiO2 ratio at 48 hours, Need for invasive mechanical ventilation and 1 more. Started Jul 2024; status: recruiting.
02
Drugs
calfactant
03
Conditions
viral pneumoniacoronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on ISRCTN12839523.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN12839523.